OBJECTIVES The purpose of this study was to investigate the differential impact of the 2 most commonly available left ventricular assist device (LVAD) types on the right (RV) and left (LV) ventricles using 3-dimensional (3D) echocardiography-based analysis of ventricular morphology.
W orldwide use of continuous-flow left ventricular assist devices (cfLVADs) is growing. Additionally, an increasing number of patients are being considered for destination therapy, and as a result, patients are being supported for increasingly longer periods of time (1, 2) . Accordingly, there is a growing need to find more optimal ways to manage these patients, an anatomic impact on the native heart. If so, device location not only may impact how the left ventricle responds to changes in speed, but may also impact, via different effects on the septum, right ventricular (RV) geometry, size, and function (7) (8) (9) . We hypothesized that 3-dimensional (3D) echocardiographyderived parameters of size and shape of the 2 ventricles may provide additional information in this context. We therefore performed 3D echocardiographic imaging during hemodynamic ramp studies in patients supported with either a centrifugal cfLVAD (HVAD) or an axial cfLVAD (HMII) to determine how device speed influences global left ventricular (LV) and RV sizes and shapes, including an analysis of septal geometry. Our aims were: 1) to determine how device speed influences LV and RV size and shape, including septal geometry; and 2) to test the feasibility of 3D echocardiographic analysis during the cfLVAD ramp study.
METHODS
We prospectively considered 63 consecutive ramp studies performed in patients with either a centrifugal (HVAD) or an axial (HMII) cfLVAD who were referred for a clinically indicated ramp test with right heart catheterization for LVAD speed adjustment.
Patients with poor 2D and/or 3D image quality or who did not meet ramp study safety criteria (see the following text) or who were undergoing a ramp test for reasons other than speed optimization were excluded from the analysis. Thirty-five patients were thereby selected. Of these 35, 4 did not complete the full ramp protocol. The final cohort consisted of 31 patients, including 19 with an HMII and 12 with an HVAD ( Table 1) . The study was approved by the institutional review board, and all patients provided informed consent.
All tests were performed in the catheterization laboratory. The overall methods employed in this study for hemodynamic assessment have been detailed previously (6) . At the initiation of the study, pump speeds were lowered to 2,300 revolutions per minute (RPM) in patients with HVAD and 8,000 RPM in patients with HMII pumps. After a 5-min stabilization period, echocardiographic, hemodynamic, and device flow, power, and pulsatility index values were taken. After completion of data acquisition, device speeds were increased by 100-RPM increments for HVAD patients and by 400-RPM increments for HMII patients. After a 2-min stabilization period, hemodynamic parameters were recorded. 3D echocardiographic images were acquired at every other speed setting, that is, at 200-RPM increments for HVAD patients and at 800-RPM increments for HMII patients. This procedure was repeated until 1 of the following occurred: 1) a maximum speed of 3,200 RPM was reached for HVAD patients or 12,000 RPM for HMII patients; 2) a suction event; or 3) a decrease in LV end-diastolic diameter to <30 mm. To simplify the graphical presentation and pooling of data, ramp speed settings were labeled from Stage I (lowest speed) to Stage V (highest speed). 
3D Ventricular Shape Analysis During The RAMP Test -2 0 1 7 : ---3D TRANSTHORACIC ECHOCARDIOGRAPHY. 3D transthoracic echocardiography (TTE) full-volume datasets of the LV and RV using electrocardiogram gating over 4 to 6 consecutive cardiac cycles during a single breath-hold (10) were obtained (iE33 ultrasound, X5-1 transducer, Philips, Amsterdam, the Netherlands).
Effort was made to maximize frame rate by imaging the RV and LV separately in order to decrease the sector width, and excluding the atria from the dataset to minimize depth. 3D TTE images of the LV were acquired from an LV-focused apical 4-chamber view, whereas a modified apical 4-chamber view focused on the RV was used for the RV. DATA AND STATISTICAL ANALYSIS. The numbers of patients that achieved successive stages of the ramp protocol are presented in 
Addetia et al. 
RESULTS
Baseline characteristics, as well as the breakdown between the HMII and HVAD subgroups, are presented in Table 1 . The mean results of the 2D and 3D
echocardiographic parameters for each stage are summarized in Table 3 for both cfLVADs. Patients were an average of 58 AE 11 years of age, and 35% had cfLVADs implanted for ischemic cardiomyopathy.
Devices were used for destination therapy in 71% of patients. There were no significant differences between the HMII and HVAD groups in terms of age, sex distribution, ischemic etiology of cardiomyopathy, or reason for cfLVAD implantation. reached a maximum speed of 9,600 RPM ( Table 2 , top). Addetia et al.
3D Ventricular Shape Analysis During The RAMP Test -2 0 1 7 : ---Typical 3D images of the LV at the highest and lowest RPMs (superimposed) are shown in Figure 2A .
Increasing pump speed resulted in decreases in chamber volume with a mean decrease in average volume of 127 AE 78 ml (p < 0.01) from lowest to highest speed setting ( Figure 3A) . In 16 of 19 (84%) patients, LV volumes decreased by $20% from the lowest to the highest speed setting. The progressive decrease in chamber volume was likely due to the LV walls moving toward the center, with some shortening of the base-to-apex dimension (mean base-toapex dimension 9.6 AE 1.1 cm at the lowest RPM vs. Table 3) . In contrast to the HMII, LV conicity and sphericity did not change significantly with increasing pump speeds in HVAD patients ( Figure 3D ).
The RV showed an overall trend to larger volumes with increasing cfLVAD speed by w22 AE 42 ml 
Addetia et al.
3D Ventricular Shape Analysis During The RAMP Test INTEROBSERVER VARIABILITY. Interobserver variability for volume and shape parameters as reflected by percent variability was 15% for LV volume, 11% for RV volume, 7% for LV sphericity, 9% for RV free-wall curvature, and 7% for RV septal curvature.
DISCUSSION
The incidence of heart failure is increasing at an alarming rate, with more than 700,000 new cases being diagnosed each year in the United States (2,14). Previous studies based on 2D echocardiographic measurements have shown that HVADs result in less of a reduction in LV chamber diameter with increasing speed compared with HMII pumps (16, 17) .
Recently, we reported that these pumps provide similar overall flows in the normal working range of speed (6), therefore, a possible explanation for the differential shape changes seen in this study during unloading is the location of the pumps in the body.
The HMII pump is located subdiaphragmatically, likely resulting in inferior displacement of the LV apex due to the pull of the inflow cannula. By contrast, the HVAD pump is inserted intrathoracically at the LV apex, resulting in less distortion of the LV apex (6) ( Figure 5) . In this way, it is possible that the HVAD pump causes less deformation at the base of the heart due to the limited space in the chest.
RV CHANGES AT HIGHER LVAD SPEEDS. The use of 2D echocardiography to optimize LVAD speed settings is a relatively recent practice, and the impact of echocardiography-guided LVAD speed adjustment on outcomes is unknown (3, 6, 14, 15) . The ability to measure RV and LV volumes and endocardial shape during incremental ramp test stages enables appreciation for the counteracting effects of LVAD speed on the RV. On one hand, increased speed leads to decreased pulmonary capillary wedge pressure, thereby reducing the afterload on the RV and facilitating RV function. On the other hand, increasing speeds result in increased venous return to the RV and septal shift toward the LV, which increases RV preload and potentially decreases RV contractility due to the abnormal geometry. At low-to-moderate speeds, these effects counterbalance each other, so there is no net effect on RV size and function. At higher LVAD speeds, the septal shift and increased venous return appear to dominate. The pump speed at which the balance tips can be identified if RV size parameters are systematically measured throughout the ramp study to determine the "cross-over point" between LV decompression and RV enlargement. One possible concern is that setting a pump speed higher than this cross-over point could result in clinically relevant RV failure, which could manifest over time However, further studies are warranted to better understand this possibility.
In keeping with the "cross-over" point, it is noteworthy that, at least in HMII pumps, RV septal curvature changes from the lowest to highest speed, suggesting that a calculated measure of septal curvature from 2D images could also be used to choose a more physiological LVAD speed. Interestingly, not all patients showed an increase in curvature from lowest to highest speed settings. Some of this In the HMII cohort, on average, the interventricular septum (top, far left), became more convex, bulging into the LV when comparing the lowest to the highest speed settings. This is illustrated on 2D echocardiography in a representative patient, bottom left. The yellow arrows illustrate septal bulging. Meanwhile, the RV free-wall became flatter at increased speeds. In the HVAD cohort, on average, the curvature of the interventricular septum did not change significantly when comparing the lowest to the highest speed settings (top, right, and 2-dimensional image in a representative patient, bottom right). Mean RV free-wall curvature did not change when comparing lowest to highest speed setting (top, far right). Abbreviations as in Figures 1 and 2 . The HMII is located subdiaphragmatically (left), whereas the HVAD pump is inserted intrathoracically at the LV apex (right). Abbreviations as in Figures 1 and 2 .
3D Ventricular Shape Analysis During The RAMP Test variability may be due to inflow cannula orientation, which differs significantly between patients.
Alternatively, the variability in septal shifts could be determined by net LV volume reduction and RV overload regardless of the inflow cannula orientation. Further study is required to better understand this finding.
As a final point, in our study, 3D echocardiography was feasible in only 56% of patients, in part due to the difficulties associated with patient positioning. Most patients had to be scanned in the supine position because simultaneous right heart catheterization was being performed. We only included patients with adequate LV and RV 3D imaging. If only 1 chamber could be imaged, the patient was not included because we were interested in the paired response of the LV and RV. Additionally, 3D imaging was challenging in obese patients, in those with poor 2D image quality, and in those with very large ventricles, which were difficult to fit in the 3D sector. Some of these had to be excluded. In the non-LVAD population, feasibility for 3D LV dataset acquisition is in the 85% range.
However, feasibility of 3D RV acquisition is lower.
Given these difficulties, development of a 2D ramp protocol including apical RV-focused views to assess RV septal curvature, as well as the "cross- 3D Ventricular Shape Analysis During The RAMP Test -2 0 1 7 : ---
